Lonza has conjugates project

May 2007
ICIS Chemical Business;5/21/2007, Vol. 2 Issue 67, p36
Trade Publication
The article reports on the antibody drug conjugates project of Lonza. The antibody drug conjugates consist of a highly active chemical substance coupled with a biotechnologically manufactured antibody. The conjugates can be used in targeted treatment of cancers. Lonza is operating a laboratory-scale production unit in Visp, Switzerland.


Related Articles

  • Antibody Drug Conjugate (ADC) Analysis with SEC--MALS.  // LC-GC Asia Pacific;Mar2014, Vol. 17 Issue 1, p36 

    This article discusses the resurgence in the development of antibody-drug conjugates (ADC) as target-directed therapeutic agents for cancer treatment. Topics discussed include the Drug Antibody Ratio and a method for (DAR) determination based on SEC-MALS. Automation of component analysis is also...

  • Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Trail, Pamela A.; King, H. Dalton; Dubowchik, Gene M. // Cancer Immunology, Immunotherapy;May2003, Vol. 52 Issue 5, p328 

    Monoclonal antibodies (mAb) directed to tumor-associated antigens (TAA) or antigens differentially expressed on the tumor vasculature have been covalently linked to drugs that have different mechanisms of action and various levels of potency. The use of these mAb immunoconjugates to selectively...

  • Maturing antibody-drug conjugate pipeline hits 30. Mullard, Asher // Nature Reviews Drug Discovery;May2013, Vol. 12 Issue 5, p329 

    The article focuses on the 30 antibody-drug conjugates (ADC) which are in clinical trials for solid tumors and blood cancer as of May 2013. It says that ADCs in development phase can rescue monoclonal antibody (mAb) in the preclinical stage which fails to provide sufficient cancer killing...

  • Fine-Chemical Producers Make Targeted Investments. Van Arnum, Patricia // Pharmaceutical Technology;Apr2013, Vol. 37 Issue 4, p114 

    The article focuses on the examination of development in pharmaceutical companies from 2012 to 2013. It says that Lonza continuous its expansion on its small-molecule custom-manufacturing business. It states that Carbogen Amcis formed a partnership with ADC Biotechnology for antibody drugs...

  • AACR Roundup.  // BioWorld Today;10/22/2013, Vol. 24 Issue 203, p9 

    The article presents news briefs related to the biotechnology industry as of October 2013. The results of a Phase II clinical trial of Angiochem Inc.'s paclitaxel-peptide drug conjugate for patients with breast and brain cancer have been completed. Sanofi SA has released the data of its Phase I...

  • Industrial R&D glimpsed.  // Nature Biotechnology;Nov2007, Vol. 25 Issue 11, p1219 

    The article reports that few of the technologies featured in the journal come from research and development in established biotechnology firms in the U.S. One is the antibody linker technology which was developed at Seattle Genetics Inc. by Peter Senter. There were already several attempts to...

  • Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Doronina, Svetlana O; Toki, Brian E; Torgov, Michael Y; Mendelsohn, Brian A; Cerveny, Charles G; Chace, Dana F; DeBlanc, Ron L; Gearing, R Patrick; Bovee, Tim D; Siegall, Clay B; Francisco, Joseph A; Wahl, Alan F; Meyer, Damon L; Senter, Peter D // Nature Biotechnology;Jul2003, Vol. 21 Issue 7, p778 

    We describe the in vitro and in vivo properties of monoclonal antibody (mAb)-drug conjugates consisting of the potent synthetic dolastatin 10 analogs auristatin E (AE) and monomethylauristatin E (MMAE), linked to the chimeric mAbs cBR96 (specific to Lewis Y on carcinomas) and cAC10 (specific to...

  • Drug design: Increasing stability of ADCs. Crunkhorn, Sarah // Nature Reviews Drug Discovery;Nov2014, Vol. 13 Issue 11, p812 

    The article focuses on the importance of maleimide in improving the stability of antibody-drug conjugates (ADCs) for the treatment of cancer.

  • Impact of conjugate Haemophilus influenzae type b (Hib) vaccine introduction in South Africa. von Gottberg, A.; de Gouveia, L.; Madhi, S. A.; du Plessis, M.; Quan, V.; Soma, K.; Huebner, R.; Flannery, B.; Schuchat, A.; Klugman, K. P. // Bulletin of the World Health Organization;Oct2006, Vol. 84 Issue 10, p811 

    Objective To analyse trends in reported invasive Haemophilus influenzae disease in South Africa within the first five years of introduction of conjugate Haemophilus influenzae type b (Hib) vaccine in the routine child immunization schedule. Methods We used national laboratory-based surveillance...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics